ARA-290
Documentation & standards
- How to Read a Peptide Certificate of Analysis (COA)
- Peptide Storage and Handling: Temperature, Light and Stability
- Research-Use-Only Compliance: What the Label Obligates
Non-hematopoietic peptide derived from the erythropoietin sequence, studied at the innate repair receptor in neuroinflammation and tissue-protection research endpoints.
Mix and match any items — discount applies automatically at checkout.
Reminder email when it's time to reorder. No card on file. Cancel anytime from your account — or email support@aresresearchlab.com.
Earn 84 loyalty points on this purchase · 100 pts = $5 off
Create a Research Account to unlock full batch data, COAs, and priority releases.
Intended strictly for controlled laboratory receptor and pathway research.
What is ARA-290 (cibinetide)?
ARA-290, also referred to as cibinetide, is a short synthetic peptide engineered from a region of the erythropoietin (EPO) sequence. It is described in the literature as a non-hematopoietic EPO-derived peptide, meaning it was designed to engage the innate repair receptor rather than the receptor complex associated with red blood cell production.
Laboratory work with ARA-290 examines signaling through the innate repair receptor — described as a heteromer of the EPO receptor and the β-common receptor subunit — along with neuroinflammatory markers, tissue-protection measurements, and nerve-related endpoints in defined experimental systems. This page describes the compound and those studied endpoints without extending conclusions beyond them.
ARA-290 COA and batch verification
No ARA-290 analytical report file is attached to this listing, so no report is cited or presented here as independently viewable. Verification for research material supplied under this catalog follows the documented process: match the identifier on the received unit through the public batch lookup, and review the published verification standards before use.
ARA-290 research material specifications
| Compound | ARA-290 (cibinetide) |
|---|---|
| Origin | Peptide derived from the erythropoietin (EPO) sequence |
| Class | Non-hematopoietic EPO-derived research peptide |
| Pathway studied | Innate repair receptor (EPO receptor / β-common receptor heteromer) |
| Research focus | Neuroinflammation, tissue-protection, and nerve-related research endpoints |
| Purity specification | ≥99% |
| Physical form | Lyophilized powder in a sealed glass vial |
| Available vial size | 10 mg |
| Attached reports | None on file for this listing — qualified verification wording applies |
| Storage | Refrigerated, dry, and protected from light; follow batch documentation |
Innate repair receptor research context
Wang RL et al., “Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke” (2024), PMID 38488446. Listed for receptor-pathway research context only.
ARA-290 research questions
+What is ARA-290?
ARA-290, also referred to as cibinetide, is a synthetic 11-amino-acid peptide derived from a region of the erythropoietin (EPO) sequence. It is supplied here as laboratory research material.
+Why is ARA-290 described as non-hematopoietic?
ARA-290 was engineered from the EPO structure so that it interacts with the innate repair receptor rather than the classical erythropoietin receptor complex associated with red blood cell production. That distinction is the basis for how the peptide is described in published literature.
+Which pathway is studied in ARA-290 research?
Published work examines signaling through the innate repair receptor, described as a heteromer of the EPO receptor and the β-common receptor subunit, in defined experimental systems.
+Which endpoints appear in ARA-290 literature?
Reported endpoints include neuroinflammatory markers, tissue-protection measurements, and small-fiber and nerve-related measures in laboratory and animal models. This page describes those studied endpoints only.
+Is an ARA-290 analytical report available?
No ARA-290 analytical report file is attached to this listing, so none is cited here. Researchers should match the identifier on the received unit through the public batch lookup and review the verification standards page before use.
+What ARA-290 format is offered?
ARA-290 is supplied as sealed lyophilized research material in a 10 mg vial. Current offers appear on this page.
+What is the listed purity specification?
The catalog specification is ≥99%. A specification is not the same as a batch result, so documentation associated with the received unit should be reviewed separately.
Read the ARA-290 research
ARA-290 (cibinetide): a non-hematopoietic peptide derived from the erythropoietin sequence, studied at the innate repair receptor.
Read article →How ARA-290 (cibinetide) is described at the innate repair receptor — EPO receptor and beta-common subunit signalling, neuroinflammation and tissue-protection endpoints.
Read article →Researcher Reviews
Sign in with the account that placed your order to leave a verified review.
Ask the Lab
No public questions yet — be the first to ask.